UC
Oncology · 2011–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab Adjuvant treatment of high-risk muscle invasive urothelial carcinoma (MIUC) after radical resection in patients who have received prior neoadjuvant… | Mar 2024 | Deferred | input received Medical Oncology Group |
| enfortumab vedotin First-line treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer in patients who have not received prior systemic therapy. | Nov 2024 | Recommended with restriction | 11 individuals BEAT Bladder Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| nivolumab First-line treatment of cisplatin-eligible adult patients with unresectable or metastatic urothelial carcinoma. | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · BEAT Bladder Cancer Australia · Medical Oncology Group |
| enfortumab vedotin Treatment of patients with locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer who have progressed on or after a platinum-containing… | Feb 2023 | Deferred | 1 individuals Medical Oncology Group |
| avelumab Maintenance treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial carcinoma in patients whose disease has not progressed following… | Mar 2022 | Recommended with restriction | no section in document |
| enfortumab vedotin Treatment of patients with locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer who have progressed on or after a platinum-containing… | Mar 2022 | Not recommended | 1 individuals Rare Cancers Australia · BEAT Bladder Cancer Australia · Medical Oncology Group |
| avelumab Maintenance treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial carcinoma in patients whose disease has not progressed following… | Mar 2021 | Recommended with restriction | input received BEAT Bladder Cancer Australia · Rare Cancers Australia · Medical Oncology Group · Society for Medical Oncology Magnitude of Clinical Benefit · Eastern Cooperative Oncology Group |
| durvalumab Treatment of patients with locally advanced or metastatic urothelial cancer who have disease progression during or following platinum-based chemotherapy. | Jul 2019 | Not recommended | 1 individuals BEAT Bladder Cancer Australia |
| vinflunine Treatment of adult patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior… | Jul 2017 | Not recommended | none received |
| pembrolizumab Treatment of patients with locally advanced or metastatic urothelial cancer after failure of a platinum-containing regimen. | Nov 2017 | Not recommended | 9 individuals Rare Cancer Australia · Medical Oncology Group |
| vinflunine Treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure of a prior platinum-containing… | Nov 2015 | Not recommended | none received |
| vinflunine Treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing… | Nov 2011 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · BEAT Bladder Cancer Australia · Rare Cancers Australia · Society for Medical Oncology Magnitude of Clinical Benefit · Eastern Cooperative Oncology Group · Rare Cancer Australia
What the PBS pays
$1,089M in government benefit over 2024–25, across 127,978 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| durvalumab | $175.6M |
| nivolumab | $85.2M |
| avelumab | $71.8M |
| enfortumab vedotin | $17M |
Appraised elsewhere
NICE, in England and Wales, has appraised 10 technologies for this condition, recommending 5 and declining 2. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nivolumabNivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) | TA1141 | terminated | 2026-03 |
| enfortumab vedotinEnfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | recommended restricted | 2025-09 |
| nivolumabNivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | recommended restricted | 2022-08 |
| enfortumab vedotinEnfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | terminated | 2022-06 |
| avelumabAvelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | recommended restricted | 2022-05 |
| atezolizumabAtezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | recommended restricted | 2021-10 |
| pembrolizumabPembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | not recommended | 2021-04 |
| pembrolizumabPembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | terminated | 2021-02 |
| atezolizumabAtezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | recommended restricted | 2018-06 |
| vinflunineVinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | not recommended | 2013-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.